Jens Lohr
Director of Immunotherapy and Cellular and Regenerative Medicine · Univ of Utah Sch of Med
Credentials: · · · · ·
History
Present
- 2000–2002
Broad Institute of Massachusetts Institute of Technology & Harvard University
- 1993–1997
Ruprecht-Karls-University of Heidelberg Faculty of Medicine
Research
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Nature · 2013 · 4,258 citations
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
Nature Communications · 2017 · 843 citations
Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy
Cancer Cell · 2014 · First of 22 authors · 819 citations
36 papers · 10 as a fellow
12 papers
9 papers
- AY
8 papers
- NR
8 papers
7 papers
6 papers
- GH
5 papers · 1 as a resident
Grants
- 2011–2028
Integrative Oncogenomics of Multiple Myeloma
National Cancer Institute · P01
Project lead · $554.2K · Dana-Farber Cancer Inst
- 2023–2027
Liquid Biopsy in Myeloma to Inform Outcome and Treatment Decisions
National Cancer Institute · R37
Contact PI · $1.5M · Utah State Higher Education System--University of Utah
- 2015–2020
Determining the Mutational Landscape of Circulating Multiple Myeloma Cells
National Cancer Institute · K08
Contact PI · $885.6K · Dana-Farber Cancer Inst